Transitional Cell Carcinoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

CG Oncology
CG OncologyIRVINE, CA
1 program
1
CG0070 Adenovirus VectorPhase 2/31 trial
Active Trials
NCT01438112TerminatedEst. Jun 2016
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
1
vinfluninePhase 2
JAVLOR® Online Non-Interventional TrialN/A1 trial
Active Trials
NCT01103544Completed200Est. Aug 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CG OncologyCG0070 Adenovirus Vector
Pierre FabreJAVLOR® Online Non-Interventional Trial

Clinical Trials (2)

Total enrollment: 200 patients across 2 trials

NCT01438112CG OncologyCG0070 Adenovirus Vector

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Start: Mar 2014Est. completion: Jun 2016
Phase 2/3Terminated
NCT01103544Pierre FabreJAVLOR® Online Non-Interventional Trial

JAVLOR® Online Non-Interventional Trial

Start: Apr 2010Est. completion: Aug 2013200 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space